Here’s what you need to know:
1. At present, the state only pays for the effective — but expensive — hepatitis C drug treatments if a patient is in the final two stages of liver damage.
2. The review board recommended that the state cover treatment for patients in the final three stages of liver damage, along with all women of child-bearing age — since the disease can be transmitted to newborn children.
3. Others, including the ACLU, argue that the state should offer treatment to all hepatitis C patients.
4. If the state decides not to cover all patients, the ACLU says they will file a federal lawsuit against the state. The ACLU says that the state is required, by federal law, to provide Medicaid patients with necessary care, which includes hepatitis C treatment.
5. The final decision on this coverage will be determined by the Department of Health Care Policy and Financing next month.
More articles on gastroenterology and endoscopy:
AGA releases findings from “IBS in America” survey: 5 takeaways
Study suggests ginger root is a possible IBD treatment: 5 insights
FDA clarifies recommendations on Custom Ultrasonics’ reprocessors: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
